Equity Profile

RMD

ResMed Inc.

Health CareHealth Care Equipment$28.8B

Apr30Thu

Post-Earnings Recap

ReportedQ3-2026After Close4:05 PM EDT

ResMed Inc. Beats on EPS, Stock Up 0.89%

Metric	Actual	Expected	Surprise
EPS	$2.86	$2.81	+2.58%
Revenue	N/A	$1.4B	N/A

management commentary, guidance changes, and full analysis available with Pro.

ResMed Inc. Beats on EPS, Stock Up 0.89%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$2.86	$2.81	+2.58%
Revenue	N/A	$1.4B	N/A

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, and the analysis is based solely on numerical results.

What It Means

ResMed's earnings report showed a positive surprise in EPS, which likely contributed to the stock's 0.89% increase. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future outlook.

Company Snapshot

ResMed Inc. (RMD) is a leading company in the health care equipment sector, focusing on innovative solutions for sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profits.

$2.81

Revenue

Total revenue reflects the company's ability to grow its sales, which is essential for long-term sustainability and investor confidence.

$1.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

ResMed Inc. (RMD) is a leading company in the health care equipment sector, focusing on innovative solutions for sleep apnea and chronic obstructive pulmonary disease (COPD). With a market cap of $31 billion, ResMed is positioned to benefit from increasing global demand for respiratory care and sleep health solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q2-2026, ResMed reported an EPS of $2.81, exceeding analyst expectations by 4.58%. However, there was no revenue figure reported, which leaves some uncertainty about overall performance.

Management Promises & Guidance

Continue to innovate in sleep and respiratory care technologies.
Expand market presence in emerging regions.
Focus on enhancing customer experience and support.

Expectations

Wall Street Expectations

Analysts expect ResMed to report strong earnings, with a consensus EPS of $2.81. The company has a solid track record of beating earnings estimates, which could lead to positive market reactions.

Bull Case

If ResMed exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides weak guidance, it could raise concerns about its growth prospects, resulting in a negative market reaction.

Key Metrics to Watch

EPS

$2.81

Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profits.

Revenue

$1.4B

Total revenue reflects the company's ability to grow its sales, which is essential for long-term sustainability and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will ResMed's EPS exceed the consensus estimate of $2.81?

A beat on EPS could reinforce investor confidence in the company's growth trajectory and operational efficiency.

What guidance will management provide regarding revenue growth?

Clear guidance on revenue growth is crucial for understanding the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate ResMed's ability to capitalize on the growing demand for sleep and respiratory care solutions, especially in emerging markets.

Supporting Evidence

ResMed has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in health care spending could favor companies like ResMed that provide essential medical equipment.

Key Risk

If ResMed's revenue growth exceeds $1.5 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether ResMed can sustain its growth amid increasing competition and changing healthcare dynamics.

Bull Confirmed If

An EPS of $2.85 or higher, coupled with revenue exceeding $1.5 billion, would confirm the bull case.

Bear Confirmed If

An EPS below $2.72 or revenue falling short of $1.4 billion would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.64%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors are expecting volatility.

Options are pricing ±9.6% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

17.3%

Calls (96K)P/C Ratio: 0.26Puts (61K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests the stock could rise by about 0.08%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss on earnings could lead to a decline, with historical patterns suggesting an average drop of around 0.0%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in sleep apnea and respiratory care.
2Any changes in guidance for revenue growth in emerging markets.
3Insights on competitive pressures and how ResMed plans to address them.
4Management's commentary on cost management and operational efficiencies.
5Trends in customer demand and feedback on existing products.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

CINFReported

Cincinnati Financial Corporation

RecapView

Apr27

CCKReported

Company Snapshot

ResMed Inc. (RMD) is a leading company in the health care equipment sector, focusing on innovative solutions for sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profits.

$2.81

Revenue

Total revenue reflects the company's ability to grow its sales, which is essential for long-term sustainability and investor confidence.

$1.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q2-2026, ResMed reported an EPS of $2.81, exceeding analyst expectations by 4.58%. However, there was no revenue figure reported, which leaves some uncertainty about overall performance.

Management Promises & Guidance

Continue to innovate in sleep and respiratory care technologies.
Expand market presence in emerging regions.
Focus on enhancing customer experience and support.

Expectations

Wall Street Expectations

Analysts expect ResMed to report strong earnings, with a consensus EPS of $2.81. The company has a solid track record of beating earnings estimates, which could lead to positive market reactions.

Bull Case

If ResMed exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides weak guidance, it could raise concerns about its growth prospects, resulting in a negative market reaction.

Key Metrics to Watch

EPS

$2.81

Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profits.

Revenue

$1.4B

Total revenue reflects the company's ability to grow its sales, which is essential for long-term sustainability and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will ResMed's EPS exceed the consensus estimate of $2.81?

A beat on EPS could reinforce investor confidence in the company's growth trajectory and operational efficiency.

What guidance will management provide regarding revenue growth?

Clear guidance on revenue growth is crucial for understanding the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate ResMed's ability to capitalize on the growing demand for sleep and respiratory care solutions, especially in emerging markets.

Supporting Evidence

ResMed has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in health care spending could favor companies like ResMed that provide essential medical equipment.

Key Risk

If ResMed's revenue growth exceeds $1.5 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether ResMed can sustain its growth amid increasing competition and changing healthcare dynamics.

Bull Confirmed If

An EPS of $2.85 or higher, coupled with revenue exceeding $1.5 billion, would confirm the bull case.

Bear Confirmed If

An EPS below $2.72 or revenue falling short of $1.4 billion would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.64%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that investors are expecting volatility.

Options are pricing ±9.6% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

17.3%

Calls (96K)P/C Ratio: 0.26Puts (61K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests the stock could rise by about 0.08%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss on earnings could lead to a decline, with historical patterns suggesting an average drop of around 0.0%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in sleep apnea and respiratory care.
2Any changes in guidance for revenue growth in emerging markets.
3Insights on competitive pressures and how ResMed plans to address them.
4Management's commentary on cost management and operational efficiencies.
5Trends in customer demand and feedback on existing products.